|
Turning
tides for Cymbiotics
Nandini Patwardhan speaks to Raj Barathur, President and CEO
of Cymbiotics, as he unveils the strategies
the US based company has employed to foray into the burgeoning
Indian market.
Moving
Northwards
NDDS has always been an integral part of drug discovery. Today,
there are very few pure players in India catering to this
niche segment. Ethypharm India, a wholly owned subsidiary
of Ethypharm SA, France is one of them. Vanessa Mahapatra
tracks the journey of this focused player.
Dynamism
in SE Asia
The emerging OTC markets, including those of South East Asia,
are performing well above par, writes Nicholas Hall.
‘The
secret is in assumptions’
Price is what we pay and value is what we get. Valuation is
key to successful acquisitions. Raman Manglorekar, Principal
Pharma Division, AT Kearney talks about different aspects
of valuation in conversation with Katya Naidu.
‘LifeConEx
is localised to meet Indian conditions’
LifeConEx is a partnership between DHL Global Forwarding and
Lufthansa Cargo and has forayed into Indian drug logistics
industry. Arshiya Khan finds out this venture's offerings
in India in conversation with Christoph Remund, the CEO-DHL
Global Forwarding.
|
